MD - MEDNAX Inc Stock Price, Fair Value and News

7.74USD-0.05 (-0.64%)Market Closed

Market Summary

USD7.74-0.05

Market Closed

-0.64%

MD Alerts

Big fall in earnings (Y/Y)

MD Stock Price

View Fullscreen

MD RSI Chart

MD Valuation

Market Cap

651.3M

Price/Earnings (Trailing)

-9.23

Price/Sales (Trailing)

0.33

EV/EBITDA

67.97

Price/Free Cashflow

5.63

MD Price/Sales (Trailing)

MD Profitability

EBT Margin

-3.06%

Return on Equity

-8.24%

Return on Assets

-3.26%

Free Cashflow Yield

17.75%

MD Fundamentals

MD Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

0.83%

Rev. Growth (Qtr)

-0.27%

MD Earnings

Earnings (TTM)

-70.6M

Earnings Growth (Yr)

-71.6%

Earnings Growth (Qtr)

103.25%

Breaking Down MD Revenue

Last 7 days

-5.8%

Last 30 days

-12.1%

Last 90 days

-16.7%

Trailing 12 Months

-43.3%

How does MD drawdown profile look like?

MD Financial Health

Current Ratio

1.72

Debt/Equity

0.72

Debt/Cashflow

0.19

MD Investor Care

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

0.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0B	0	0	0
2023	2.0B	2.0B	2.0B	2.0B
2022	1.9B	2.0B	2.0B	2.0B
2021	1.7B	1.8B	1.8B	1.9B
2020	1.8B	1.8B	1.8B	1.7B
2019	3.0B	2.6B	2.2B	1.8B
2018	3.5B	3.5B	3.5B	3.5B
2017	3.3B	3.3B	3.4B	3.5B
2016	2.9B	3.0B	3.1B	3.2B
2015	2.5B	2.6B	2.7B	2.8B
2014	2.2B	2.3B	2.4B	2.4B
2013	1.9B	2.0B	2.1B	2.2B
2012	1.6B	1.7B	1.8B	1.8B
2011	1.5B	1.5B	1.6B	1.6B
2010	1.3B	1.3B	1.4B	1.4B
2009	0	1.1B	1.2B	1.3B
2008	0	0	0	1.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MEDNAX Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	pickert curtis	gifted	-	-	-12,923	evp, chief operating officer
Mar 01, 2024	wood lee	sold (taxes)	-45,402	9.15	-4,962	evp, natl & market operations
Mar 01, 2024	swift james d	sold (taxes)	-136,683	9.15	-14,938	chief executive officer
Mar 01, 2024	pickert curtis	sold (taxes)	-83,814	9.15	-9,160	evp, chief operating officer
Mar 01, 2024	moore mary ann e	sold (taxes)	-53,683	9.15	-5,867	evp, general counsel & sec
Mar 01, 2024	richards c marc	sold (taxes)	-196,066	9.15	-21,428	evp, chief financial officer
Dec 14, 2023	swift james d	sold	-55,219	9.58	-5,764	chief executive officer
Dec 14, 2023	moore mary ann e	sold	-9,331	9.62	-970	evp, general counsel & sec
Dec 14, 2023	moore mary ann e	sold	-11,063	9.62	-1,150	evp, general counsel & sec
Jun 14, 2023	swift james d	sold	-186,549	14.14	-13,193	chief executive officer

Which funds bought or sold MD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-9.6	-8,484	330,154	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-381,644	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.44	15,642	804,877	-%
May 16, 2024	Tidal Investments LLC	new	-	441,561	441,561	0.01%
May 16, 2024	Pineridge Advisors LLC	unchanged	-	78.00	1,073	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-67.28	-13,743,100	7,493,660	-%
May 15, 2024	Quarry LP	reduced	-29.93	-7,416	22,939	-%
May 15, 2024	Atom Investors LP	new	-	356,195	356,195	0.04%
May 15, 2024	SEGALL BRYANT & HAMILL, LLC	reduced	-1.98	848,617	15,693,600	0.29%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	added	434	43,750	52,939	-%

Are Funds Buying or Selling MD?

Are funds buying MD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MD

No. of Funds

MD Alerts

Big fall in earnings (Y/Y)

Unveiling MEDNAX Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	alliancebernstein l.p.	9.4%	7,887,018	SC 13G/A
Feb 13, 2024	vanguard group inc	12.37%	10,393,239	SC 13G/A
Feb 12, 2024	earnest partners llc	5.7%	4,818,090	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	5.2%	4,409,901	SC 13G
Jan 22, 2024	blackrock inc.	16.2%	13,600,467	SC 13G/A
May 10, 2023	alliancebernstein l.p.	10.0%	8,392,304	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	7.8%	6,468,122	SC 13G/A
Feb 14, 2023	earnest partners llc	7.9%	6,546,580	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	11.72%	9,738,017	SC 13G/A

Recent SEC filings of MEDNAX Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report

Peers (Alternatives to MEDNAX Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

MEDNAX Inc News

Latest updates

MEDNAX Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.3%	495	496	507	501	491	514	490	486	482	499	493	473	447	417	461	415	441	459	455	439	427
Operating Expenses	-21.2%	479	608	466	452	461	478	443	436	443	431	434	423	421	384	440	381	430	418	406	396	387
S&GA Expenses	-100.0%	-	53.00	57.00	58.00	59.00	51.00	58.00	61.00	61.00	59.00	67.00	71.00	67.00	55.00	66.00	60.00	67.00	59.00	63.00	63.00	59.00
EBITDA Margin	-38.0%	0.01*	0.01*	0.10*	0.10*	0.10*	0.08*	0.10*	0.10*	0.10*	0.12*	0.11*	0.10*	-	-	-	-	-	-	-	-	-
Interest Expenses	5.1%	11.00	10.00	10.00	11.00	10.00	10.00	10.00	8.00	12.00	17.00	18.00	17.00	18.00	27.00	27.00	28.00	28.00	28.00	30.00	31.00	30.00
Income Taxes	126.0%	4.00	-14.56	9.00	11.00	7.00	4.00	10.00	12.00	-7.40	13.00	12.00	7.00	-4.95	6.00	7.00	3.00	1.00	4.00	7.00	7.00	-1.51
Earnings Before Taxes	105.6%	8.00	-138	31.00	39.00	21.00	28.00	39.00	43.00	-28.35	54.00	43.00	38.00	0.00	10.00	4.00	10.00	-17.41	14.00	20.00	13.00	11.00
EBT Margin	-26.4%	-0.03*	-0.02*	0.06*	0.06*	0.07*	0.04*	0.05*	0.06*	0.05*	0.07*	0.05*	0.03*	-	-	-	-	-	-	-	-	-
Net Income	103.2%	4.00	-124	21.00	28.00	14.00	30.00	31.00	27.00	-21.19	48.00	31.00	35.00	18.00	-64.30	-41.04	-672	-18.71	9.00	-1,255	-8.24	-242
Net Income Margin	-16.6%	-0.04*	-0.03*	0.05*	0.05*	0.05*	0.03*	0.04*	0.04*	0.05*	0.07*	0.01*	-0.03*	-	-	-	-	-	-	-	-	-
Free Cashflow	-277.1%	-122	69.00	80.00	89.00	-100	99.00	83.00	82.00	-97.48	44.00	61.00	54.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.3%	2,168	2,220	2,326	2,306	2,320	2,348	2,332	2,370	2,341	2,723	2,646	2,555	2,484	3,348	3,425	3,387	4,320	4,146	4,291	5,639	5,706
Current Assets	-11.8%	427	483	421	398	409	428	424	459	440	841	788	752	665	1,549	1,651	688	941	732	965	986	1,057
Cash Equivalents	-89.1%	8.00	73.00	21.00	6.00	6.00	10.00	9.00	14.00	7.00	387	358	338	270	1,124	295	132	312	108	25.00	36.00	46.00
Net PPE	-1.7%	74.00	76.00	75.00	73.00	73.00	73.00	72.00	72.00	72.00	70.00	73.00	68.00	81.00	76.00	79.00	98.00	100	73.00	94.00	93.00	89.00
Goodwill	0.7%	1,393	1,384	1,532	1,532	1,532	1,532	1,532	1,532	1,529	1,505	1,497	1,487	1,482	1,478	1,481	2,165	2,710	1,480	2,635	4,070	4,066
Liabilities	-4.3%	1,312	1,371	1,358	1,363	1,410	1,456	1,473	1,524	1,464	1,826	1,800	1,746	1,717	2,600	2,620	2,561	2,832	2,647	2,811	2,914	2,926
Current Liabilities	-36.4%	247	389	350	320	284	427	352	329	270	427	398	351	327	444	488	384	346	542	501	441	415
Long Term Debt	-100.0%	-	618	622	625	-	632	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	0.8%	856	849	968	942	910	892	859	845	877	897	846	809	767	748	805	827	1,487	1,499	1,479	2,725	2,780
Retained Earnings	-197.3%	-145	149	-25.18	-46.57	-74.86	-89.06	-118	-149	-176	-155	-202	-233	-268	-286	-222	-179	491	510	501	1,757	1,801
Additional Paid-In Capital	0.3%	1,003	1,000	996	992	987	984	981	997	1,054	1,050	1,045	1,039	1,032	1,029	1,024	1,005	995	988	978	967	978
Shares Outstanding	0.0%	84.00	84.00	84.00	84.00	84.00	83.00	82.00	85.00	85.00	85.00	85.00	85.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Float	-	-	-	-	1,177	-	-	-	1,243	-	-	-	1,895	-	-	-	1,252	-	-	-	2,051	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-277.1%	-122,624	69,250	79,938	89,054	-100,917	98,686	83,330	82,407	-97,482	44,236	61,102	53,587	-82,188	-11,866	169,935	188,435	-141,884	135,297	159,199	120,032	-56,817
Share Based Compensation	1.4%	3,067	3,024	3,164	3,126	3,009	3,236	4,120	4,336	4,435	4,021	5,495	5,735	3,717	2,922	22,946	5,731	7,443	5,898	6,659	9,864	10,989
Cashflow From Investing	-30.7%	-16,238	-12,424	-14,004	-10,398	-11,350	-11,241	-6,088	-13,352	-26,273	-15,584	-41,214	14,089	-10,364	840,611	-3,441	-1,439	-20,220	156,977	-26,888	-18,943	-8,691
Cashflow From Financing	1705.3%	76,204	-4,747	-50,604	-78,931	108,567	-86,289	-82,662	-62,146	-256,457	825	-131	851	-761,661	586	-4,133	-366,650	366,039	-209,499	-143,150	-107,085	66,664
Buy Backs	-	887	-	133	11.00	775	1,470	21,477	64,398	1,166	-	2,474	251	1,994	-2.00	5,452	501	2,542	356	415	65,527	78,982

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MD Income Statement

2024-03-31

Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 495,101	$ 491,008
Operating expenses:
Practice salaries and benefits	369,138	362,235
Practice supplies and other operating expenses	31,085	30,720
General and administrative expenses	60,198	59,059
Depreciation and amortization	10,308	8,953
Transformational and restructuring related expenses	8,480	0
Total operating expenses	479,209	460,967
Income from operations	15,892	30,041
Investment and other income	2,013	634
Interest expense	(10,599)	(10,390)
Equity in earnings of unconsolidated affiliate	518	427
Total non-operating expenses	(8,068)	(9,329)
Income before income taxes	7,824	20,712
Income tax provision	(3,789)	(6,506)
Net Income	4,035	14,206
Unrealized holding gain on investments, net of tax of $20 and $227	60	604
Total comprehensive income	$ 4,095	$ 14,810
Net income:
Basic	$ 0.05	$ 0.17
Diluted	$ 0.05	$ 0.17
Weighted average common shares:
Basic	82,863	81,894
Diluted	83,275	82,318

MD Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,998	$ 73,258
Short-term investments	107,473	104,485
Accounts receivable, net	283,749	272,313
Prepaid expenses	12,532	13,525
Income taxes receivable	5,193	7,565
Other current assets	9,578	12,308
Total current assets	426,523	483,454
Property and equipment, net	74,340	75,639
Goodwill	1,393,249	1,384,166
Intangible assets, net	18,759	21,240
Operating and finance lease right-of-use assets	70,278	70,294
Deferred income tax assets	101,942	102,852
Other assets	83,074	82,165
Total assets	2,168,165	2,219,810
Current liabilities:
Accounts payable and accrued expenses	207,035	350,798
Current portion of debt and finance lease liabilities, net	16,409	14,913
Current portion of operating lease liabilities	21,034	21,076
Income taxes payable	2,804	2,159
Total current liabilities	247,282	388,946
Line of credit	80,000	0
Long-term debt and finance lease liabilities, net	613,347	618,421
Long-term operating lease liabilities	47,873	47,238
Long-term professional liabilities	255,870	251,284
Deferred income tax liabilities	34,105	34,308
Other liabilities	33,492	30,552
Total liabilities	1,311,969	1,370,749
Commitments and contingencies
Shareholders' equity:
Preferred stock; $.01 par value; 1,000 shares authorized; none issued	0	0
Common stock; $.01 par value; 200,000 shares authorized; 84,008,436 and 84,018,023 shares issued and outstanding, respectively	840	840
Additional paid-in capital	1,002,946	999,906
Accumulated other comprehensive loss	(2,154)	(2,214)
Retained deficit	(145,436)	(149,471)
Total shareholders' equity	856,196	849,061
Total liabilities and shareholders' equity	$ 2,168,165	$ 2,219,810

About MEDNAX Inc

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

CEO	Dr. James D. Swift M.D.
WEBSITE	pediatrix.com
INDUSTRY	Healthcare Plans
EMPLOYEES	5250

MEDNAX Inc Frequently Asked Questions

What is the ticker symbol for MEDNAX Inc? What does MD stand for in stocks?

MD is the stock ticker symbol of MEDNAX Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MEDNAX Inc (MD)?

As of Fri May 17 2024, market cap of MEDNAX Inc is 651.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MD stock?

You can check MD's fair value in chart for subscribers.

What is the fair value of MD stock?

You can check MD's fair value in chart for subscribers. The fair value of MEDNAX Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MEDNAX Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MEDNAX Inc a good stock to buy?

The fair value guage provides a quick view whether MD is over valued or under valued. Whether MEDNAX Inc is cheap or expensive depends on the assumptions which impact MEDNAX Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MD.

What is MEDNAX Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MD's PE ratio (Price to Earnings) is -9.23 and Price to Sales (PS) ratio is 0.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MEDNAX Inc's stock?

In the past 10 years, MEDNAX Inc has provided -0.18 (multiply by 100 for percentage) rate of return.